OPEN END-TURBO-OPTIONSSCHEIN - ROCHE GS Stock

Certificat

DE000TD8DPB6

Market Closed - BOERSE MUENCHEN 09:40:09 2024-05-24 am EDT
0.49 EUR -2.00% Intraday chart for OPEN END-TURBO-OPTIONSSCHEIN - ROCHE GS
Current month+28.95%
1 month+22.50%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-24 0.49 -2.00%
24-05-23 0.5 0.00%
24-05-22 0.5 -7.41%
24-05-21 0.54 0.00%
24-05-17 0.54 0.00%

Real-time BOERSE MUENCHEN

Last update May 24, 2024 at 09:40 am EDT

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer HSBC
WKN TD8DPB
ISINDE000TD8DPB6
Date issued 2017-02-20
Strike 183.6 CHF
Maturity Unlimited
Parity 100 : 1
Emission price 0.46
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 2.16
Lowest since issue 0.14

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
230.4 CHF
Average target price
279.8 CHF
Spread / Average Target
+21.46%
Consensus